Wednesday’s Top Stock Gainers: AEZS, KBIO, BONT, STRP, GENE

Share

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)

The stock increased 48.83% or $3.75 on November 25, hitting $11.43. About 17.26M shares traded hands or 1141.73% up from the average. AEZS has risen 1905.26% since April 24, 2015 and is uptrending. It has outperformed by 1906.39% the S&P500.

Out of 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $11 is the highest target while $1 is the lowest. The $11 average target is -3.76% below today’s ($11.43) stock price. Aeterna Zentaris Inc. was the topic in 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained the stock on November 24 with “Buy” rating. Canaccord Genuity upgraded the shares of AEZS in a report on November 9 to “Buy” rating.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical firm engaged in developing treatments in oncology, endocrinology and women’s health. The company has a market cap of $50.36 million. The Firm has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. It currently has negative earnings. The Company’s drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds , which are in pre-clinical development.

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) The stock increased 44.73% or $8.23 on November 25, hitting $26.63. About 8.62 million shares traded hands or 284.82% up from the average. KBIO has risen 4924.53% since April 24, 2015 and is uptrending. It has outperformed by 4925.65% the S&P500.

The institutional sentiment increased to 0.45 in Q2 2015. Its up 0.04, from 0.41 in 2015Q1. The ratio increased, as 8 funds sold all KaloBios Pharmaceuticals Inc shares owned while 3 reduced positions. 2 funds bought stakes while 3 increased positions. They now own 6.90 million shares or 22.14% less from 8.87 million shares in 2015Q1.

Opus Point Partners Management Llc holds 0.28% of its portfolio in KaloBios Pharmaceuticals Inc for 746,467 shares. Harbourvest Partners Llc owns 57,604 shares or 0.01% of their US portfolio. Moreover, Blair William & Co Il has 0% invested in the company for 53,635 shares. The California-based California Public Employees Retirement System has invested 0% in the stock. Citigroup Inc, a New York-based fund reported 2,745 shares.

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $75.88 million. The Firm is focused on the development of monoclonal antibody therapeutics for diseases that represent a burden to society and to patients and their families. It currently has negative earnings. The Firm operates through the development of pharmaceutical products segment.

Bon-Ton Stores Inc (NASDAQ:BONT)

The stock increased 36.36% or $0.64 on November 25, hitting $2.4. About 2.65 million shares traded hands or 661.24% up from the average. BONT has declined 67.35% since April 24, 2015 and is downtrending. It has underperformed by 66.22% the S&P500.

Out of 3 analysts covering Bon-Ton Stores (NASDAQ:BONT), 0 rate it “Buy”, 2 “Sell”, while 1 “Hold”. This means 0 are positive. $3.50 is the highest target while $2 is the lowest. The $2.50 average target is 4.17% above today’s ($2.4) stock price. Bon-Ton Stores was the topic in 6 analyst reports since August 21, 2015 according to StockzIntelligence Inc. Telsey Advisory Group maintained the stock on November 20 with “Underperform” rating. Zacks upgraded the shares of BONT in a report on August 21 to “Sell” rating. The institutional sentiment is 0.78 in Q2 2015. Its the same as in 2015Q1. The ratio is the same, as 18 funds sold all Bon-Ton Stores Inc shares owned while 19 reduced positions. only 13 funds bought stakes while 16 increased positions. They now own 10.01 million shares or 8.49% less from 10.94 million shares in 2015Q1. Brigade Capital Management Lp holds 0.46% of its portfolio in Bon-Ton Stores Inc for 1.79 million shares. Deltec Asset Management Llc owns 376,008 shares or 0.38% of their US portfolio. Moreover, Teton Advisors Inc. has 0.2% invested in the company for 616,755 shares. The Pennsylvania-based Emerald Advisers Inc Pa has invested 0.08% in the stock. Wellington Shields & Co. Llc, a New York-based fund reported 25,500 shares. Since June 2, 2015, the stock had 0 buys, and 2 selling transactions for $8,597 net activity. Mansker Jimmy Dale sold 550 shares worth $1,925. The Bon-Ton Stores, Inc. is a department store operator. The company has a market cap of $37.48 million. The Firm offers a range of brand-name fashion apparel and accessories for women, men and children. It currently has negative earnings. It operates approximately 270 stores in 26 states in the Northeast, Midwest and upper Great Plains under the Bon-Ton, Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers nameplates, encompassing a total of approximately 25 million square feet. Straight Path Communications Inc (NYSEMKT:STRP) The stock increased 30.34% or $2.91 on November 25, hitting $12.5. About 3.42 million shares traded hands or 228.85% up from the average. STRP has declined 42.75% since April 24, 2015 and is downtrending. It has underperformed by 41.63% the S&P500.

The institutional sentiment increased to 2.79 in Q2 2015. Its up 1.83, from 0.96 in 2015Q1. The ratio improved, as 7 funds sold all Straight Path Communications Inc shares owned while 12 reduced positions. 30 funds bought stakes while 23 increased positions. They now own 3.84 million shares or 34.61% more from 2.85 million shares in 2015Q1.

Farmstead Capital Management Llc holds 1.49% of its portfolio in Straight Path Communications Inc for 90,312 shares. Tcs Capital Management Llc owns 76,500 shares or 1.27% of their US portfolio. Moreover, Archer Capital Management L.P. has 0.93% invested in the company for 223,397 shares. The New York-based National Asset Management Inc. has invested 0.83% in the stock. Thompson Davis & Co. Inc., a Virginia-based fund reported 13,750 shares.

Since March 18, 2015, the stock had 0 insider buys, and 3 selling transactions for $543,098 net activity. Pi Zhouyue sold 77 shares worth $3,128. Jonas Davidi sold 6,000 shares worth $240,000. Weld William F sold 8,000 shares worth $161,215.

Straight Path Communications Inc. is a communications asset company. The company has a market cap of $116.16 million. The Company’s businesses consist of interest in Straight Path Spectrum, Inc. and Straight Path IP Group, Inc. (Straight Path IP Group). It currently has negative earnings. The Firm has two business divisions: Straight Path Spectrum, which holds, leases and sells fixed wireless spectrum, and Straight Path IP Group, which holds intellectual property primarily related to communications over the Internet and the licensing and other businesses related to this intellectual property.

Genetic Technologies Limited (ADR) (NASDAQ:GENE)

The stock increased 25.00% or $0.74 on November 25, hitting $3.7. About 10.33M shares traded hands or 700.78% up from the average. GENE has declined 21.28% since April 24, 2015 and is downtrending. It has underperformed by 20.15% the S&P500.

Genetic Technologies Limited is a molecular diagnostics company. The company has a market cap of $35.78 million. The Firm offers predictive testing and assessment tools to help physicians manage women’s health. It currently has negative earnings. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

COMMENTS: